Evelo Biosciences, Inc.
EVLO
$0.0003
-$0.0002-40.00%
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 20.65M | 23.89M | 27.54M | 29.91M | 33.59M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 73.84M | 92.50M | 104.63M | 108.47M | 114.94M |
| Operating Income | -73.84M | -92.50M | -104.63M | -108.47M | -114.94M |
| Income Before Tax | -81.44M | -99.52M | -109.05M | -113.60M | -119.16M |
| Income Tax Expenses | 905.00K | 1.03M | 959.00K | 930.00K | 483.00K |
| Earnings from Continuing Operations | -82.35 | -100.55 | -110.01 | -114.53 | -119.64 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -82.35M | -100.55M | -110.01M | -114.53M | -119.64M |
| EBIT | -73.84M | -92.50M | -104.63M | -108.47M | -114.94M |
| EBITDA | -72.27M | -90.62M | -102.64M | -106.41M | -112.86M |
| EPS Basic | -13.35 | -18.30 | -22.59 | -29.15 | -35.58 |
| Normalized Basic EPS | -7.92 | -11.02 | -13.94 | -18.03 | -22.15 |
| EPS Diluted | -13.35 | -18.30 | -22.59 | -29.15 | -35.58 |
| Normalized Diluted EPS | -7.92 | -11.02 | -13.94 | -18.03 | -22.15 |
| Average Basic Shares Outstanding | 34.00M | 22.02M | 20.23M | 17.36M | 14.55M |
| Average Diluted Shares Outstanding | 34.00M | 22.02M | 20.23M | 17.36M | 14.55M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |